Sign up to save your podcasts
Or
Share Experts Talk AML #4 : Anti-fungal Prophylaxis and Safety in AML
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Experts Talk AML #4 : Anti-fungal Prophylaxis and Safety in AML
A discussion between Dr. Daniel A. Pollyea and Dr. Michelle Geddes (Fall 2021)
In this final episode of the AML podcast series, Dr. Pollyea and Dr. Geddes share their experience with using antifungal prophylaxis with novel AML treatment approaches. They review the risk factors and discuss caveats regarding the impact of antifungals on venetoclax dosing regimens, and, most importantly, on the efficacy in treating the disease.
Daniel A. Pollyea, MD, MS Associate Professor of Medicine Clinical Director of Leukemia Services Robert H. Allen MD Chair in Hematology Research Division of Hematology University of Colorado School of Medicine
Michelle Geddes, MD, FRCPC Clinical Associate Professor, Division of Hematology, University of Calgary
This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.
View all episodes
By Various Topics on AML and CLL ManagementA discussion between Dr. Daniel A. Pollyea and Dr. Michelle Geddes (Fall 2021)
In this final episode of the AML podcast series, Dr. Pollyea and Dr. Geddes share their experience with using antifungal prophylaxis with novel AML treatment approaches. They review the risk factors and discuss caveats regarding the impact of antifungals on venetoclax dosing regimens, and, most importantly, on the efficacy in treating the disease.
Daniel A. Pollyea, MD, MS Associate Professor of Medicine Clinical Director of Leukemia Services Robert H. Allen MD Chair in Hematology Research Division of Hematology University of Colorado School of Medicine
Michelle Geddes, MD, FRCPC Clinical Associate Professor, Division of Hematology, University of Calgary
This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.